Good day, welcome to the RadNet Fourth Quarter 2025 Financial Results Conference Call. All participants will be in a listen- only mode. Should you need assistance, please signal conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touch tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Mr. Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet. Please go ahead, sir. Thank you. Good morning, ladies and gentlemen, and thank you for joining Dr. Howard Berger and me today to discuss RadNet's fourth quarter and full- year 2025 financial results. On this call, we also have invited Kees Wesdorp, President and CEO of Digital Health, and Sham Sokka, Chief Operating and Technical Officer of Digital Health, who will share additional information about this morning's announcement of the acquisition of Paris, France-based Gleamer. Before we begin today, we'd like to remind everyone of the safe harbor statement under the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning anticipated future financial and operating performance, RadNet's ability to continue to grow the business by generating patient referrals and contracts with radiology practices, recruiting and retaining technologists, receiving third-party reimbursement for diagnostic imaging services, successfully integrating acquired operations, generating revenue and Adjusted EBITDA for the acquired operations as estimated, among others, are forward-looking statements within the meaning of the safe harbor. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause RadNet's actual results to differ materially from the statements contained herein. These risks and uncertainties include those risks set forth in RadNet's reports filed with the SEC from time to time, including RadNet's annual report on Form 10-K for the year ended December 31st, 2025 to be filed shortly. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date it is made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. With that, I'd like to turn the call over to Dr. Berger. Thank you, Mark. Good morning, everyone, thank you for joining us today. On today's call, Mark and I plan to provide you with highlights from our fourth quarter and full- year 2025 results, give you more insight into factors which affected this performance, and discuss our future strategy and provide more information about this morning's acquisition announcement. After our prepared remarks, we will open the call to your questions. I'd like to thank all of you for your interest in our company and for dedicating a portion of your day to participate in our conference call this morning. Let's begin. I'm very pleased with the performance in the fourth quarter. It was the strongest quarter in the company's history, with record revenue and Adjusted EBITDA. Total company revenue increased 14.8% to $547.7 million, and Adjusted EBITDA increased 16.9% from last year's fourth quarter to $87.7 million. Digital Health fourth quarter 2025 revenue, excuse me, increased 48.2% to $27.9 million, and Digital Health's Adjusted EBITDA increased 8.9% to $4.9 million from last year's fourth quarter. Imaging center revenue continues to be driven by increased demand in virtually all of our markets, benefiting from the growing utilization of diagnostic imaging within healthcare, as well as the continuing shift of procedural volumes away from more expensive hospital alternatives to ambulatory freestanding centers. As a result, we experienced 14.1% aggregate and 9.6% same-center advanced imaging procedural volume growth in this year's fourth quarter relative to last year's same quarter. I am highlighting the growth in advanced imaging because MRI, CT, and PET/ CT are responsible for over 60% of RadNet's revenue and are important drivers of margin and profitability. To this end, revenue benefited from the continuing shift in modality mix towards advanced imaging. During the fourth quarter, advanced imaging represented 28.6% of RadNet's procedural volume, an increase of 178 basis points from last year's same quarter. This increase is a function of the overall industry trend of more of these exams being ordered as a result of technological advances in these modalities. Significant capital investment we have made in the last few years in advanced imaging equipment for growth and replacement, and the implementation of TechLive and AI-powered dynamic scheduling. 2025 was a year of significant investment. During 2025, we opened seven de novo facilities in markets where there were backlogs which we required additional capacity for, or where we needed access points to service identified patient populations. These centers should be material contributors to long-term performance and growth in 2026 and beyond. During 2025, we expanded several of our joint venture partnerships with de novo builds and acquisitions. We are in conversation to establish several new health system joint venture opportunities. Currently, 151 of RadNet's 418 centers, or 36.1%, are held within health system partnerships. Health systems continue to seek long-term strategies around outpatient imaging and have recognized that cost-effective and efficient freestanding centers will continue to capture market share from hospitals as payers and patients migrate their site of care towards lower cost, high-quality solutions. Our health system partners have been instrumental in increasing RadNet's procedural volume with their physician relationships. During 2025, we were active with acquisitions in both the imaging centers and Digital Health operating segments. During 2025, we expanded into our largest margin markets through additional acquisitions of imaging facilities in California, New York, and Maryland. Within Digital Health during 2025, we acquired iCAD, See-Mode, and CIMAR, which have already been integrated into the DeepHealth product portfolio solutions. Subsequent to year-end, in January, we expanded into three new markets with the acquisitions of 13 centers in Southwest Florida and entered Indiana with the acquisition of six facilities of Northwest Radiology and a single center in Virginia. Of course, this morning, we announced the completion of Gleamer, which Kees and Sham will speak about in more detail shortly. Within Digital Health, we are continuing to build the most comprehensive portfolio of AI-powered solutions designed to transform both the workflow and clinical capabilities within radiology. These solutions are critical to addressing the constrained labor market for technologists, center-level administrative personnel, and radiologists. We believe there will be a day where every procedure RadNet performs is put through artificial intelligence as part of the clinical and reporting workflow. Efficiency, productivity, and accuracy will improve with the use of the tools, and RadNet is committed to both implementing these solutions in its core imaging centers and commercializing them for sale to the rest of the industry. It is patients who will ultimately benefit as both service levels and health outcomes will improve. Throughout 2025, we continued to manage liquidity and financial leverage. At the year-end 2025, RadNet's cash balance was $776 million, and the net debt to Adjusted EBITDA leverage ratio was approximately 1.0x. While we have been acquisitive so far during 2026 with the acquisitions in Southwest Florida, Indiana, Virginia, and the Gleamer transaction announced this morning, we remain committed to operating the company with low leverage. At this time, I'd like to turn the call back over to Mark to discuss some of the highlights of our fourth quarter and full- year 2025 performance, as well as discuss our 2026 guidance. Thank you, Howard. I'm now going to briefly review our fourth quarter and full- year 2025 performance and attempt to highlight what I believe to be some material items. I will also give some further explanation of certain items in our financial statements, as well as provide some insights into some of the metrics that drove our fourth quarter and full year 2025 performance. I will also provide 2026 guidance levels, which were released in this morning's financial results press release. In my discussion, I will use the term Adjusted EBITDA, which is a non-GAAP financial measure. The company defines Adjusted EBITDA as earnings before interest, taxes, depreciation, and amortization, and excludes losses or gains on the disposal of equipment, other income or loss on debt extinguishments, and non-cash equity compensation. Adjusted EBITDA includes equity and earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries and is adjusted for non-cash or extraordinary and one-time events taking place during the period. A full quantitative reconciliation of Adjusted EBITDA to net income or loss attributable to RadNet, Inc. common shareholders is included in our earnings release. This quarter, we are also introducing a second non-GAAP measure pertaining to the Digital Health segment called annual recurring revenue, otherwise known as ARR. The company defines ARR as a key subscription economy metric representing the predictable, normalized, annualized value of contracted recurring revenue generated from customers from active customer contracts. ARR includes subscription fees, recurring support fees, and contracted usage charges, and excludes one-time non-recurring fees such as implementation, hardware sales, professional services, consulting, and one-off training. With that said, I'd now like to review our fourth quarter and full- year 2025 results. As many of you have seen in the financial release this morning, we had a very strong fourth quarter. While I won't recap all the financial information that's contained in the earnings report, here are some of the highlights. Fourth quarter total company revenue and Adjusted EBITDA were both quarterly records. Revenue increased 14.8%, and Adjusted EBITDA increased 16.9% from last year's fourth quarter. The Digital Health segment also exhibited strong growth in the quarter, with revenue growing 48.2% and Adjusted EBITDA growing 8.9% from last year's fourth quarter. The strong revenue growth was partially the result from the contribution of iCAD, acquired in July, which otherwise would have seen 25.9% growth without the contribution of iCAD. Fourth quarter adjusted earnings per share for RadNet essentially was flat at $0.23 per share versus $0.04 per share for the last year's fourth quarter. Also benefiting the fourth quarter was the continued shift in business mix in favor of advanced imaging that Dr. Berger mentioned in his earlier remarks. Higher acuity advanced imaging drives more revenue per procedure and improved Adjusted EBITDA. The strong ending to the year caused us to meet or exceed the 2025 original guidance levels and guidance ranges we increased during quarters throughout the year for revenue, Adjusted EBITDA, and free cash flow for the imaging center segment. Within Digital Health, revenue finished at $92.7 million above the original and within the amended guidance ranges, and Adjusted EBITDA of $15.5 million, which finished within the original and revised guidance levels, despite having integrated the negative EBITDA businesses during the year of both iCAD and See-Mode. We finished 2025 with a strong cash and liquidity position. At year-end, we had $767 million of cash on the balance sheet, full availability of a $282 million revolving credit facility, and a term loan that is priced at SOFR plus 225 basis points. Continued improvement in revenue cycles have lowered our DSOs, or Days Sales Outstanding, to a RadNet record low of 29.5 days, which we believe to be one of the best in the industry. With regards to our financial leverage at December 31st, 2025, unadjusted for bond and term loan discounts, we had $323.5 million of net debt, which is our total debt at par value less our cash balance. Note that this debt balance includes RadNet's ownership percentage, or 49%, of New Jersey Imaging Network's net debt of $27.8 million, for which RadNet is neither a borrower nor guarantor. At year-end, our net debt to Adjusted EBITDA leverage ratio was approximately 1x. As some of you may have seen, we released 2026 guidance ranges in conjunction with our financial results press release this morning. While I'm not going to run through all the numbers on this call, I will emphasize some important points. We anticipate growth next year to exceed the target growth we presented at the Investor Day in New York back in November. 2026 guidance anticipates 17%-19% imaging center revenue growth relative to 2025, resulting from contributions of continued increases in same center performance, further tuck-in acquisitions, reimbursement efforts driving more favorable pricing, and de novo center openings. We are also expecting EBITDA growth to exceed that of revenue, creating margin improvement. Free cash flow is expected to grow 29%-41% from 2025 levels. Embedded in these guidance numbers are approximately 4% growth in same center labor costs, as well as the recent impact of severe winter weather conditions in our Mid-Atlantic and Northeast regions. Within Digital Health, 2026 guidance implies revenue growth between 45% and 55% from 2025 performance. 2026 growth will be driven by sales of the DeepHealth portfolio of AI-powered workflow and clinical solutions and related products such as TechLive and further contribution from the acquisitions of iCAD, See-Mode, CIMAR and Gleamer. In this morning's press release, we introduced a new metric to track the progress of the Digital Health division, otherwise known as ARR. We will continue to update this metric each quarter and at year-end to give more transparency into the growth and the future progress of the Digital Health division. At December 31st, 2025, ARR for the Digital Health division was $75.4 million. We are anticipating ARR will approach $140 million at the end of 2026. This growth is partially from the contribution of Gleamer, which is in the neighborhood of an additional $30 million of ARR, with the remainder of the growth coming from SaaS-based revenue recognized from the licensing of AI-powered workflow and clinical solutions. In 2026, we also expect the proportion of Digital Health revenues, which comes from RadNet's imaging centers segment, to decrease from 45% in 2025 to about 33% in 2026. On the development side, we are anticipating a minimum of four FDA clearances during 2026, which should further advance our leadership in radiology clinical AI solutions in the areas of mammography, lung, prostate, thyroid, brain, and with this morning's announcement of the acquisition of Gleamer, the musculoskeletal system. In 2026, significant infrastructure investments will continue to be made in building sales, marketing, implementation teams to support future growth. I'd now like to turn the call over to Kees Wesdorp. Kees and Sham Sokka will provide more information about this morning's acquisition of Gleamer. Thank you, Mark. Across the globe, imaging demand continues to rise while radiologists, technologists, and other labor shortages persist. Re-engineering high volume workflows, particularly routine imaging such as X-ray, ultrasound, and mammography, is becoming essential to sustaining access, efficiency, and quality of care. For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting. The foundation of RadNet's strategy is combining the largest outpatient imaging network in the U.S. with DeepHealth's advanced clinical AI and imaging informatics platform. This combination uniquely positions RadNet to validate, deploy, and scale AI solutions at a level unmatched in the industry, both across RadNet's own network and for customers worldwide. Today, RadNet announced another major step forward in that strategy. Acquisition of Gleamer, a Paris-based leading radiology AI company to be integrated into DeepHealth. With this acquisition, DeepHealth becomes the largest provider of radiology clinical AI solutions worldwide. Gleamer is a fast-growing cloud-native software-as-a-service radiology AI company serving more than 700 customer contracts across 44 countries. Powered by more than 130 professionals, including a strong commercial team of 40 team members and more than 76 research and development team members, Gleamer has developed, commercialized, and delivered solutions to dis-support over 25 clinical indications. Its broad multimodality portfolio includes four FDA-cleared and six CE- marked clinical AI and workflow solutions, supporting more than 25 clinical indications across musculoskeletal, breast, lung, and neurologic applications. Gleamer solutions are designed to improve quality of care while reducing radiologists' workloads with automated reporting capabilities already deployed in Europe. The company has achieved annual recurring revenue, a compound annual growth exceeding 90% from 2022 to 2025, and is expected to reach approximately $30 million ARR in 2026. Together, we are now the largest provider of radiology clinical AI solutions worldwide in both the breadth of AI solutions and ARR. The combination delivers an integrated end-to-end platform that supports every stage of the radiology workflow. The combined portfolio unifies clinical and agentic AI, operational intelligence, and workflow automation in a single platform that spans patient journey efficiency, technology and operations efficiency, and AI driven diagnosis, triage, and reporting. DeepHealth now covers the entire radiology workflow from image acquisition to reporting and follow-up. At this time, I'd like to turn the call over to Sham, who will go through some more details around the acquisition and our overall strategy at DeepHealth. Thank you, Kees. This morning's acquisition of Gleamer strategically enhances DeepHealth's and RadNet in four areas. First, it expands DeepHealth's portfolio across all core imaging modalities. The integration of Gleamer's portfolio with DeepHealth's clinical AI suites for breast, chest, neuro, prostate, and thyroid creates a comprehensive portfolio unrivaled by any other radiology AI company. The combined portfolio supports screening, detection, interpretation, and follow-up across many of the most prevalent cancer types, as well as neurodegenerative and musculoskeletal conditions, including trauma and chronic diseases. With the inclusion of Gleamer's products, particularly its market-leading capabilities in X-ray, DeepHealth now provides native clinical AI solutions across MR, CT, X-ray, mammography, and ultrasound modalities, making it the worldwide leader of radiology clinical AI solutions. Second, the acquisition enhances DeepHealth's global commercial reach and scale. Gleamer's leadership in Europe, particularly across France, DACH, and broader EMEA markets, significantly strengthens DeepHealth's commercial engine. The acquisition adds more than 700 customer contracts across hospitals, imaging centers, and healthcare systems, significantly increases annual recurring revenue, and expands the global sales force with more than 40 team members, predominantly Europe and U.S.-based commercial professionals. This scale accelerates DeepHealth's global trajectory and enhances its ability to deliver transformative AI-enabled imaging solutions worldwide to customers. Third, we are leveraging Gleamer to drive operational efficiency across RadNet's highest volume workflows. Deploying Gleamer's radiology AI and workflow capabilities across RadNet's imaging network is expected to create measurable productivity gains, particularly in X-ray, which accounts for nearly 25% of RadNet's imaging volume. RadNet intends to implement an AI and an end-to-end AI-enabled workflow, beginning with triaging critical findings to accelerate interpretation of urgent cases. The acquisition will also accelerate the introduction of draft reporting capabilities, allowing radiologists to increase reading volumes with greater accuracy and standardization. As an aside, for those of you who are less familiar with the radiology workflow, what our industry calls reporting is when radiologist types or dictates his or her findings or interpretation into a clinical report that is then shared with the referring physician and patient. For many radiology exams, the reporting part can take more time and radiologist effort than the interpretation itself. This end-to-end workflow approach is designed to optimize internal resource utilization, resulting in improved operational and cost efficiencies with expected benefits beginning as early as the third quarter of 2026. Finally, fourth, looking ahead, the acquisition meaningfully advances DeepHealth's paths toward automated diagnostics. Gleamer has developed automated reporting capabilities where the AI is able to create the clinical report on behalf of the radiologist without human intervention. This feature is already in early deployment with customers in Europe. When this feature is combined with DeepHealth's AI and informatics portfolio, it brings clinical, generative, and agentic AI and imaging informatics together into an integrated offering. With this extensive expertise, DeepHealth is uniquely positioned to enable more standardized interpretation, automated draft reporting, and scalable diagnostic pathways. At this time, I'm gonna hand the call back to Kees, who will make some summary points about the implications of today's acquisition. Thank you, Sham. This acquisition really strengthens RadNet's Digital Health business strategically and operationally and expands cross-selling and upselling opportunity across its installed base. The transaction was completed with cash valued at up to EUR 230 million, inclusive of post-closing milestones. The transaction reflects Gleamer's multi-year high recurring revenue growth, cloud-native gross margins, and strong customer retention. The acquisition is expected to create meaningful growth in cost synergies, estimated at approximately $7 million run rate, and to accelerate Gleamer's path to positive Adjusted EBITDA by mid 2027, faster than it could have achieved independently. In summary, the acquisition of Gleamer is a transformative milestone for us. It establishes DeepHealth as the largest provider of radiology clinical AI solutions worldwide, expands its global footprint, strengthens operational performance across high-volume workflows, and accelerates the delivery of AI-enabled automated diagnostics. DeepHealth and Gleamer have combined and have a combined installed base of 2,700 customers. Actually, over 2,700 customers across more than 44 countries. A comprehensive portfolio including 26 FDA cleared and 22 CE mark devices supporting over 75 indications. It comes with a global footprint with over 550 employees across four continents. DeepHealth with Gleamer together anticipate achieving ARR approaching or exceeding $140 million by the end of 2026. We believe that these metrics make DeepHealth the leader in providing clinical radiology AI solutions worldwide. Together, RadNet and DeepHealth are redefining how imaging is delivered at scale with intelligence and automation to empower breakthroughs in care and unlock greater access, efficiency, and better experiences and outcomes for patients and providers worldwide. At this time, I will hand the call back to Dr. Berger, who will make some closing remarks. Thank you, Kees. Radiology is entering a new era. I am proud to be at the helm of the company that is leading this transition into an era of unprecedented demand and challenging workload environment that is critical to long-term benefit and outcomes for our patients and referring physicians. The introduction of Digital Health to the RadNet portfolio is barely over three years since we built the team that Kees and Sham will be leading forward. This particular acquisition announced today with Gleamer completes the strategy that we announced earlier at the Investor Day last year of wanting to be the leader in routine imaging, meaning mammography, X-ray, and ultrasound. The company, Gleamer, is headed by an exceptionally talented team led by Christian Allouche, that we are proud to bring into the RadNet family. This event, I believe, is a seminal event, not only in the history of RadNet, but what it represents as leading into this next era of artificial intelligence, which will be transformational for the industry and healthcare in general. The opportunity for RadNet now expands well beyond the outpatient centers and into relationships that we expect to grow deeper with hospitals and hospital systems that we are currently already joint ventured with and which we are getting significant interest from others to deal with all of the problems that radiology faces, which are primarily driven by the workforce, both from the radiologist professional and non-professionals. I look forward to our next calls, where we will be able to discuss in more detail the progress that is being made, not only in the Digital Health division, but how it's impacting RadNet and its other customers. I particularly wanna thank the Gleamer teams and the RadNet management, and all our advisors that worked very diligently to get to this day and hope that the marketplace will begin to better understand why RadNet made this commitment to Digital Health several years ago, and which we now stand on the precipice of major transformative changes. With that, we'll turn the call over to question and answers. Mark? Thank you, operator. We're ready for the question-and-answer portion of the call. Thank you. If you wish to ask a question today, please press star then one on your touch-tone phone. If you want to withdraw your question, please press star then two. At this time, we'll pause momentarily just to assemble a roster. The first question will come from Brian Tanquilut with Jefferies. Please go ahead. Hey, good morning. Maybe I'll ask the AI question. I hesitate 'cause I know this could be a one-hour discussion. When we think of, you know, non-healthcare AI companies saying that AI will disrupt radiology or can disrupt radiology, maybe, Howard, the first question is, where do you stand on that? I mean, how do you see AI being a benefit, especially for someone like RadNet? Then in the context of the acquisition of Gleamer today, and you being positioned as the largest pro, you know, owner of clinical AI assets in the space, how differentiated has RadNet become with this transaction? Thanks. Thanks, Brian. Good morning. I don't think disruption is the right term to use for the opportunities. Also I shouldn't just call them opportunities, but the critical needs that radiology has, as well as all of healthcare to transform itself and try to put less dependence on manual labor. The shortages that we have are going to continue for the foreseeable future, the demand that we are currently experiencing will be unabated because of the technological advances that are occurring on the equipment side. This is an opportunity for us to make all of the constituents in RadNet better at doing their jobs, better both in terms of productivity, accuracy, and fundamentally, lifestyle. The burden that is being placed on radiologists and our technologists, due to the enormous amount of manual effort that needs to go into seeing a patient, performing a scan, creating a report, and follow-up is becoming almost insurmountable. As opposed to other industries where perhaps there will be large replacement by AI of employees, that's not how RadNet sees the world. These are tools that will enhance productivity, allow us to continue to grow and match the demands that we have, not just from a volume standpoint, but we have to appreciate that the quality and capabilities of the new equipment is almost something that could never have been imagined even three or four years ago. And we see these cases on a daily basis. We see the impact that imaging is having. I would like everyone to reflect on the commitment we made to the DeepHealth acquisition little over six, almost six years ago, and where we have demonstrated, and others, that artificial intelligence in the breast screening area has increased early detection of cancers by 20%-22%. That is just extraordinary. While we're not curing cancers, we're finding them earlier and allowing for a better outcome. That fundamentally is really what artificial intelligence will have the capability of doing, and that is diagnosing diseases earlier to afford not only a better financial outcome and less financial burden, but also to improve the longevity and better lifestyle that people would like to achieve. I think that the issue of artificial intelligence in healthcare in general is not one that transforms the industry by simply replacing people, but making the workforce that we have that's insufficient to handle the needs that we have right now, more capable and more accurate in the work that they do. I think I'd like to think, and I've said this before, that artificial intelligence in healthcare is much different than it is almost in any other industry. I appreciate that. Mark, maybe as I think about the ARR, and I appreciate you guys sharing that with us. Any, any call-outs? Other than Gleamer here, I mean, it's showing pretty significant growth from year-end 2025 to 2026. Any, anything you can share in terms of where that, those contractors are coming from or what's providing that confidence and that level of growth year- over- year? Sure. I'll let Kees address that, and I'll chime in if anything more to add. Yeah, of course. As a reminder, we operate currently three different business domain. One is what we call Clinical AI, where obviously the Gleamer acquisition fits squarely in. The second is what we call Enterprise Imaging, which traditionally you would call PACS, is now powered by the DeepHealth OS to deliver our Diagnostic Suite. The third is Enterprise Operations, which you call traditionally our risk business. All three businesses contribute to that momentum. We see very, very good continued growth in the Clinical AI domain. We're winning contracts both in the outpatient segment as well as renowned logos in for hospital systems. We continue to build momentum in particularly in the U.S. for enterprise imaging offering with our Diagnostic Suite, partially with upgrades in our installed base, but also new wins as we roll out our broader Diagnostic Suite. The same then holds for our Enterprise Operations portfolio, which is our Operations Suite. So it's as much as installed base upselling as it is new wins, and then more for in Europe for clinical AI and U.S., a combination of clinical AI, Enterprise Operations and enterprise imaging. Commercial funnel across these three domains is developing well. One of the things that we also have done in 2025 is more deeply invest in our commercial team organically and also inorganically with the acquisition in particular of iCAD as well as service delivery. That sort of spans the plan that we've deployed last year and how we now see the commercial momentum going forward. Awesome. Thank you, guys. All right. Brian, before you go, let me add one additional point here. One of the reasons why the Gleamer acquisition was so attractive to us, as I had mentioned earlier, is rounding out our portfolio in the routine imaging space. As part of our overall strategy, particularly with our hospital partners, is to afford them the opportunity to have their entire provider network system, meaning their Physician groups, their urgent cares, their emergency rooms, all connected on the same platform. When you stop to think about in the bigger picture, what portion from a volume standpoint is contributed to imaging, it is dominated by routine imaging. Some of the tools that we're talking about here, particularly not just with AI, but also the ability to have real-time reporting that AI will substantially enhance. We're looking at opportunities within urgent care systems, within physician offices to give them the capability of providing very high quality level work, for what is not necessarily a revenue source for them, but for the delivery of care and immediacy to help the patient journey. The amount of opportunity that resides in what we like to call the nontraditional imaging provider network is extraordinarily high. Just to give some context to this, there's more than twice as many urgent care centers and more rapidly growing than there are outpatient imaging centers, across the U.S. These kind of transformative tools will allow us to enter onto another platform where we're not necessarily constrained with traditional reimbursement for claims, but rather to be part of the delivery system of healthcare that we can help the providers benefit from by, again, earlier detection and greater opportunity to advance the patient journey on as timely a basis as possible. I think you can look for opportunities that we'll be demonstrating, you know, later this year, which will enhance not only our imaging revenue by providing these, but also be a very substantial market, which is predominantly driven by routine imaging. I'll just add my two cents here just to address your question directly on the ARR side. In 2025, our ARR of Digital Health was $75 million. I'm just gonna give you a couple of pieces to bridge you to the roughly $140 million that we're anticipating in ARR at the end of 2026. If you take the $75, Brian, and you add roughly about $30 million of ARR for Gleamer, you're up at $105. Then there's about $7 million of additional ARR that just comes from the annualization of the iCAD acquisition, which we did in July. You're really the base ARR if you pro forma those two items for the year, you know, starts you at about $113. The other $27 million of ARR is the growth that Kees described with all the other products and services, both from the clinical AI side as well, the informatics, you know, and the work of the, you know, commercialization and sales and marketing teams during 2026 to sell those products and services. Perfect. Thank you, guys. Your next question will come from David MacDonald with Truist. Please go ahead. Good morning, guys, and congratulations. Got a couple of part question on Gleamer and then just one on imaging. On Gleamer, a couple of things. First of all, on the 700+ customer contracts, you talked a little bit about upselling and cross-selling. Can you just provide a little bit of context in terms of how many of those are incremental or new to RadNet? I did miss the number in terms of how many of the professionals are R&D. Just last piece, can you give any framing around as you reengineer the workflows, what type of efficiency gains you hope to achieve in some of the routine imaging areas? Yeah. Mark, let me take that. First on the customer contracts, what we shared today is that DeepHealth has over 2,000, before Gleamer, has over 2,000 customers, customer contracts, and Gleamer will add another 700. There will be some overlap, but the percentage of contracts that has, let's say, two or more overlapping solutions will be very, very minimal. In a way to think about the upsell opportunity out of the 2,700 joint contracts, we apply right now a logic of 80%-90% of those provides, given our broad clinical AI portfolio, an upsell opportunity. We're currently going into depths as of today, since close, we are going into depth with the joint team to build the plans for that and to really figure out, you know, what the nitty-gritty detail is contract by contract on what the opportunity is at hand. Sham, you wanna talk about R&D, the 76. Maybe let me do the following. It's a sales force of 40 FTE, commercially and around, let's say, up to 80 R&D. The total team is 130. Sham, you can talk a little bit more about the engineering capabilities. Yeah. Maybe just to give a bit of detail, it's both software capability as well as ML machine learning capability. The team has built foundation models to support their X-ray findings and also in the CT area, so we'll leverage that more broadly with our [audio distortion]. Sham, we lost you there. You cut out. Dave, sorry, we had. Yeah. We had a [audio distortion]. Yeah. Guys, I can jump to my next question, you know, go backwards. The radiologist is essentially looking at the images and correcting a draft report, amending to that report or just clicking accept. We think that's gonna give us the significant efficiencies on the X-ray volume itself, and that we can actually recover some of those costs and bring their time more available to do the advanced imaging studies that we're talking about that are growing at such a high rate. Okay. guys, just a second question just on the imaging side. I guess two-part question. One, just given some of the pressures that hospital systems are seeing and, you know, are expected to see on a go-forward basis, are you seeing a growing% of your pipeline leaning towards JV type of deals? secondly, on de novos, you guys have entered a handful of markets that I guess I would define as, you know, much more receptive in terms of licensing, in terms of building, et cetera. Is there an opportunity as the Floridas, the Texases of the world become a larger percentage of the portfolio that time to develop or cost to develop de novos could improve? The first part of your question, David, is without question, the number of inbound calls that we're getting from hospital systems has dramatically increased over the last, 12 to 18 months. Okay. Primarily, I think that's because the radiologist staffing shortage, is an acute problem, virtually for every hospital system, no matter what size it is. As a result, the initial calls may come into us to see if we can assist them with radiology staffing needs. Since that's not currently a core business of ours, it moves to a more comprehensive solution for them that not only, attempts to deal with where they need to transition from their current capabilities of providing tools like, the viewer or PACS and AI solutions, into ways to better grow their outpatient business and to incorporate, their physician, groups into a more, friendly and efficient, informatic system, enterprise imaging system. I would say that while we continue to see opportunities for what we like to call tuck-in acquisitions, those are being dwarfed by potentially larger opportunities with health systems that, instead of just maybe having five hospitals may have 50 or 100 hospitals. The landscape is changing out there very rapidly, and I think RadNet's capabilities are being better appreciated as perhaps, a unique company to give them, benefits, across the entire spectrum of radiology. On that note, you know, I think it's highly likely that in 2026, you know, we'll be announcing some new health system relationships as well as expanding existing ones. As far as de novos in some of the new markets that we entered into, RadNet's philosophy has always been to land and expand, not build and hold. I think you can expect that we will be discussing other acquisitions that might be opportunistic in the new markets that we've entered, as well as building centers to address the needs of some of these opportunities that I think lack the capital and resources to really take advantage of the growing demand for imaging. All of the newer acquisitions, which primarily were completed, you know, this year, the two larger ones in Indianapolis and in Southwest Florida, are actively under discussion for both of these kind of expansion opportunities, acquisitions as well as de novos, as well as the possibility of potentially in those markets, finding other joint venture partners that are consistent with our hospital strategy. Okay. Thanks very much. Thanks, Dave. The next question will come from Andrew Mok with Barclays. Please go ahead. Hi. Good morning. First, wanted to clarify this new ARR metric. In 2025, Digital Health revenue was $93 million, ARR was $75 million, there's about an $18 million difference. In 2026, it sounds like the Digital Health revenue guidance of $140 million is expected to approximate ARR of $140 million. Why is there a delta between the two metrics in 2025, and why does that go away in 2026? Thanks. Sure. I'll give my answer, and then I'll let Sham and Kees chime in. Predominantly, the difference in 2025 between the booked revenue and ARR at the end of the year was the EBCD revenue that we recognize within the Digital Health division, okay. That was predominantly the delta. That delta, though, goes at the end of 2026, remember the following, that ARR is almost-- It should be thought of as a balance sheet metric, meaning a, you know, a number at a period in time as opposed to tracking, you know, the full year's worth of revenue. By the end of 2026, you know, these are based upon signed contracts, and many of those contracts that we sign that will be part of the ARR will be signed in, you know, the, in the second half of next year or even towards year-end. That counts in the ARR but it doesn't count in the revenue for that year because those contracts might be just starting. That's why that gap, you know, is closing. As we continue to grow the SaaS-based business and sign new contracts going forward, I would expect that the ARR would exceed the booked revenue, which is a backward-looking metric, as opposed to ARR, which is a forward-looking metric. Sham, do you wanna add anything to that? Yeah, Mark, let me add a little bit also pinging back to or referring back to the Investor Day, what we presented there. Our traditional business, where we come from, is partially upfront license towards our customers and recurring revenue. Our business mix last year was, let's say, 75% from a recurring nature, and the remainder were one-off implementation fees or the EBCD program that's not necessarily recurring because it's a direct-to-consumer type of offering and so on and so forth. During Investor Day last year, we said, with growing concern with organic growth, that recurring nature of the business will grow fast because all our propositions will be offered on an ARR subscription basis. That proportion was gonna was being forecasted to reach 80%, 90% in the course of, let's say, two years. With the acquisition of Gleamer, which is a 100% ARR business, so fully recurring revenues, we significantly boosted that profile. We're achieving an equal amount of recurring revenue for next year, as well as GAAP revenue. Going forward, as we grow, accelerate the recurring revenue-based business, we can indeed expect that the recurring revenue is gonna larger versus the booked revenue. When we say ARR of 2025, it means the recurring revenue at the end of the period. It's a run rate number. Right. Understood. Okay, that's helpful. Maybe a follow-up on the free cash flow. It looks like the free cash flow in the imaging segment is up nearly 50% despite higher cash interest expense and higher CapEx. Can you walk us through the better, you know, metrics there and including any favorable items from working capital? Thanks. Yeah, sure. It's predominantly or the increase, expected increase in free cash was predominantly from the significant increase we have in EBITDA because while cash interest expense, as you correctly point out, is going up, mostly due to the fact that our cash, our expected cash income from our cash balance will go down because we've spent some of that cash, i.e., on the Gleamer acquisition as well as Indiana and Southwest Florida. The fact of the matter is that the EBITDA is going up and, you know, disproportionately to how we're growing CapEx, which you can see CapEx is fairly flat relative to last year, and the interest income, net interest expense is only slightly going up. That delta is all, you know, benefiting free cash flow. Got it. Thank you. The next question will come from Matthew Gillmor with KeyBanc. Please go ahead. Hey, thanks for the question. I wanted to ask about the EBITDA guidance. It sounds like EBITDA is absorbing some pressure from the weather in the first quarter, and then I suspect there's also some losses at Gleamer that's probably pulling down EBITDA a little bit too. I was just hoping you could quantify that so we could sort of understand what's embedded within that potential drag. Sure. Sure. The Gleamer EBITDA loss is being absorbed in the EBITDA guidance of the Digital Health division. You'll see in the press release, there's a footnote there that we're anticipating as much as $5 million EBITDA loss this year from the absorption of Gleamer. As Kees said in his remarks, we expect to get that to EBITDA positive sometime in the middle of 2027, partly from a number of cost synergies there. On the RadNet side, yes, you're correct. There's two main headwinds that are embedded in our EBITDA guidance for 2026. The first being the most significant is actually labor increases. We're anticipating over $30 million of same center labor increases in 2026, and that's embedded in our guidance, and that's roughly about 4% on average for our labor force in 2026. That was a similar amount that we absorbed in 2025. There may be some upside there as we continue to implement some of the Digital Health solutions that will automate, you know, many of the manual processes that we're doing today, and maybe we can do a little bit better than that. The second headwind that's absorbed in the guidance is the winter weather conditions that we've, you know, seen here in January, February, which will impact our first quarter. It won't impact our first. You know, assuming we have no more weather issues in March, it won't be as significant as what we saw last year. Last year's was even more extreme. That headwind is, you know, is embedded in the guidance that we put forth today. Okay, that's helpful. You know, there was a comment in the Gleamer sale announcement earlier in some of your commentary about Gleamer augmenting DeepHealth's commercial sales force. I think you mentioned Gleamer has 40 sales set. I was just wanting to get some context in terms of how DeepHealth sales force is organized and the size of that sales force and what Gleamer is bringing to the organization from its perspective. Yeah. Thank you. To put it very simple, after the iCAD acquisition, we had a little bit over 20 strong sales force in the U.S. and a few sales leaders in Europe. In the U.S., it's a mixture of a team that can sell clinical AI solutions, as well as what we call the IT infrastructure solutions for the Diagnostic Suite and the Operations Suite. In Europe, it was much more focused on clinical AI. What Gleamer does is accelerates our commercial horsepower with roughly 35 people in Europe, or I would say EMEA plus plus, and an additional five persons in the U.S. You should really see it initially as an acceleration of the momentum in Europe and a further build-out of capability in the U.S. Great. Thanks very much. The next question will come from Yuan Zhi with B. Riley Securities. Please go ahead. Thank you for taking our questions. Good morning. Understand there are many moving pieces and recent acquisitions. If you exclude the recent acquisitions of imaging centers in Florida and Indy, what are the guided organic growth for imaging center business? Yeah, thanks, Yuan. Appreciate the question. You know, I guess, are you talking about same center, growth, organic growth? Yeah. We typically build, and this year is no different, we typically build our same center performance kind of in the 3%-5% range. We try to be somewhat. You know, long term, we've seen kinda 2%-4%, but in the last five or so years, as more and more payers are getting aggressive in moving business away from the hospitals into freestanding centers, we've seen that organic growth, you know, regularly be in the mid-single digits or higher. We tend to build our guidance around growth in the 3%-5% range on a same center basis. If, you know, we are lucky enough, like what we have, you know, experienced over the last, let's say, half a decade to have that better than 3%-5%, then we'll see some upside to the guidance throughout the year. As you saw from this fourth quarter, we greatly exceeded that, you know, that 3%-5%, you know, where we saw advanced imaging, you know, on average be up 9.6% on a same center basis, you know, from the fourth quarter of 2024. You know, I think there may be some upside there, but we'll have to see, you know, as we move through the year. We won't necessarily get a good indication of that in the first quarter, you know, due to the weather conditions, or at least in January and February. I think if assuming we don't have any significant weather factors in March, you know, we might have a better feeling of it, you know, once we see March results. Yeah. Got it. With the recent addition of Gleamer, can you compare the DeepHealth ecosystem versus GE HealthCare, in compositions, in the portfolio compositions since they recently acquired that Intelerad? Where do you see some overlap competitions? Of course, we will learn more later at your upcoming event. I think I'll take that call or question. I don't see much overlap at all when it comes to artificial intelligence. The Intelerad acquisition by GE was primarily a what we call a viewer or a PACS system, which was intended to be a replacement or a upgrading of their current tools, which I think have been lagging in terms of investment and whatnot. Intelerad is primarily a hospital-based, and to a lesser extent, outpatient-based system, which we come across infrequently in the outpatient area, but which we feel is just a single component of what we are offering now in the way of AI, both from the clinical standpoint as well as the operational standpoint to enhance improvement. Layered over that is gonna be what the real driver and the opportunity here is, and that is the use of artificial intelligence, both from a clinical and a reporting standpoint, to improve overall radiologist efficiency and productivity. Where there perhaps is a departure here is the tool that GE bought, Intelerad, really focuses on just a single part of the IT infrastructure. That meaning a viewer or a PACS system that essentially presents the images and creates storage capabilities. Ours is substantially greater in terms of its impact on running the entire workflow process of the radiology department, whether it's hospital-based or outpatient-based. Got it. Maybe one quick follow-up here. If the acquisitions of recent imaging centers and Gleamer are complete, what is the net leverage ratio right now? What is the next... I'm sorry, I didn't hear the question. What is the net leverage ratio? Oh, the leverage ratio. The pro forma leverage ratio? Yeah. Well, we have completed Gleamer, once you see our first quarter numbers, we'll be levered to about 2x. Yeah, slightly less than 2x. Probably- Between 1.7x and 1.8x Yeah, maybe in the 1.6x-1.8x range. Yeah. Got it. That's all from me. Thank you. The next question will come from Larry Solow with CJS Securities. Please go ahead. Great. Good morning. Congrats on another good year and on the exciting acquisitions. First question just on Gleamer. You, you mentioned, it'll turn EBITDA positive sometime during mid 2027. I'm just curious, you know, approximate timeline when you will start integrating this technology into the imaging center and when you think it will actually drive a net benefit in your cost on that side of the business. Kees, I'm gonna let you handle that one. Kees and Sham. Yeah. Sham is basically handing it over to me. I'm delighted to take it on. We have actually taken already during diligence a light speed start to working with the team to figure out what can be deployed when. We are gonna take multiple steps here. The initial step is making sure that the current portfolio of Gleamer gets deployed, which should yield productivity impact as of Q3 this year. Meaning, faster diagnosis, finding indications that find its way automatically in a report, streamlining reading, triaging, and reporting accordingly. We expect those benefits to occur in Q3 this year also based on our experience with deploying, for instance, the See-Mode solution and so on and so forth. That's phase one, and I'll let Sham comment on that in a sec. Phase 2 is really the step towards automated reporting, where more and more you get the benefit of not just doing the diagnosis faster and better, but also alleviating the burden of creating reports. That can be done in draft reports that can include a certain amount of findings, for instance, the X-ray space. What if you could extend that also with findings from with other indications? The more indications you have there, obviously the better the draft reports will be. We're gonna take a little bit more time to develop that. It's being developed as we speak, but we would see that, you know, in the coming six to 12 to 18 months coming to fruition. Yeah. Maybe the only thing to add is, Gleamer is not only an X-ray company. Obviously we're gonna do the short X-ray, they have a very strong lumbar MR product which has a very complicated exam and has lots of measurements, automating that can create tremendous amount of efficiencies. We do a high volume of lumbar at RadNet, so that's also another area that we're gonna be bringing it in. As we now pool the teams together, it's gonna accelerate our overall roadmap. It's X-ray, it's lumbar, MSK, MR, and then some new areas that we'll develop together, we'll also see that rolling out towards the end of this year. Great. Perhaps just another question for you guys on the Digital Health. The forecasted or projected EBITDA this year, net or ex the Gleamer acquisition, it would be flat to modestly up but a little lower margin. I'm assuming you're just accelerating some of your investments into the business. I imagine that the mid to long-term outlook is probably actually improved. Can you just give us any, you know, any color on that? Correct. That's absolutely correct assumption. What we track internally is both what we call core business growth, so the organic growth from our standing business without new product development. That's performing nicely towards the growth objectives that we have portrayed during Investor Day. It also comes obviously with a very good margin that you would expect from cloud-native solutions. Secondly, we have the impact from previous year acquisitions. Remember, those acquisitions, for instance, iCAD came at a loss. Returning those around, c apturing the synergies. We've also guided, for instance, for iCAD, that that will take till mid-2026 for the break-even point. Now we're actually ahead of that plan, but that's still providing a little bit of a margin drag, margin rate drag. The third before Galaxy, is indeed exactly as you said, we are investing in our commercial team, we're investing in our service capabilities, we are investing in our regulatory capabilities, and that indeed has an impact on the margin rate. The other side of it is on the top line side, right? As you know, we're in a SaaS model, and so revenue lags, contracts, and that's the reason now we start to report on ARR, so you get a feeling of how the forward business looks like. Great. If I can just slip in one more for Mark, just on the imaging segment. You mentioned a little bit of headwind on the labor cost and the weather, probably in the first quarter or I guess it has to be the first quarter. It looks like EBITDA margin about flat year-over-year. Just curious, a lot of moving parts, but Is within that embedded, is there a net benefit from the Digital Health piece this year relative to last year that's flowing into imaging? Yeah. Because we're continuing to implement this year, we haven't put a lot in the budget in terms of the efficiencies and savings f rom Digital Health, I think that that's another area of upside, in the guidance for this year. Gotcha. Just lastly, cadence, weather obviously an impact Q1 of last year as well. How, you know, you had the fires. You know, do you expect still to grow year-over-year or just any kind of thoughts on cadence as we start the year? Thanks, Mark. Yeah. No. We certainly expect the first quarter of this year to be ahead of last year's first quarter. And while we did have some pretty bad winter storms, which I know you lived through in New York, Larry, they weren't it still wasn't as bad as the winter weather conditions and the fires from last year's first quarter. There will be an impact, and we'll be able to quantify that, you know, when we issue our first quarter results. Great. Thanks for all the color. Appreciate it. Okay. While I'm gonna, if Yuan, you're still listening, I've got some more information on your question about what would be the revenue growth year-over-year between 2025 and 2026 without the Indiana and Southwest Florida acquisitions. The Indiana and Southwest Florida acquisitions are gonna be responsible for about $120 million of revenue growth in 2026, Yuan, so you can take roughly $120 million out of your model and then recalculate what those growth rates would be without those acquisitions. I think we have one more question before we end the call. The next question will come from Jim Sidoti with Sidoti & Company. Please go ahead. Hi. Good morning. Thanks for taking the questions. Two quick ones. One, can you tell us what the cash paid out for those acquisitions in Indiana and Florida were in the first quarter? Yeah, sure. You'll see it laid out in our 10-K, which is being filed today. For the Florida, Southwest Florida acquisition, we paid roughly about $65 million for that. For Indiana, I believe it was about $9 million. Okay. All right. Do you in the past, you said you plan to open about 10 new centers a year, 10 newly built centers. What's the expectation for 2026? Between 11 and 13 centers is what we anticipate opening by the end of this year. Okay. All right. It's been a long call. I think that's it for me. I appreciate it. Okay. Thank you. This will conclude our question- and- answer session. I would like to turn the conference back over to Dr. Howard Berger for any closing remarks. Please go ahead. Again, I would like to take the opportunity to thank all of our shareholders for their continued support and the employees of RadNet for their dedication and hard work. This is an exciting time for RadNet, and we were glad to share that with our shareholders and stakeholders here. You can be certain that management will continue to endeavor to be a market leader that provides great services with an appropriate return on investment for all stakeholders. Thank you for your time today, and I look forward to our next call. Good day. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.